EWTX Company Profile and Key Details

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) closed at $30.61 USD, losing -$0.35 (-1.13%) from the previous close of $30.96. The stock is currently mid-range between its 52-week high and low $12.15 and $35.00. With a market capitalization of about $3.28 billion, Edgewise Therapeutics, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.25). Key stats such as the average daily volume over the past year has been around 910.64 thousand shares, volume is running light vs its 52-week average. Headquartered in Boulder, CO, Edgewise Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Kevin Koch, the company employs approximately 117 people and listed since March 26, 2021. Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases.

EWTX has shown sold momentum, gaining 19.06% over the past week and 90.77% over the past quarter, though year-to-date performance is up 15.78%. Short-term trend indicators are bearishly aligned (SMA20 0.14%, SMA50 9.3%, SMA200 57.84%). The stock’s 14-day RSI is 53.52 (neutral), while the ATR of 1.57 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.79% below its high and over 179.81% above its low. Average 10-day trading volume of 1.35 million shares is significantly above the 3-month average of 852.78 thousand, indicating heightened recent market interest.

Edgewise Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.56. This means the shares are trading above this model’s fair value.

Edgewise Therapeutics, Inc. generated EPS of -$1.58 over the past year. Five-year average earnings growth is -49.0%. Wall Street analysts project EPS growth of -11.87% annually over the next five years. The latest quarter delivered EPS of -$0.47. The next quarter is forecast at -$0.43. Next year's EPS is expected at -$33.36. Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 1 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $50.00 to $20.00. The high target offers 61.5% upside. The low target suggests -35.4% downside. The mean target is $37.90. This offers 22.42% upside. Edgewise Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended February 26, 2026, missed forecasts by 9.3%. The prior quarter beat by -3.63%. Over the last six quarters, Apple has recorded several small beats. These include -2.7% in November 07, 2024.

Edgewise Therapeutics, Inc. has 105.35 million shares outstanding. The public float is 60.53 million shares, elevated short interest at 11.36% of float. This equals 10.19 million shares. The short ratio is 17.04 days. Institutional investors hold 116.86% of the float. Insiders own 0.44%. OrbiMed Genesis GP LLC holds 13.50 million shares, Novo Holdings A/S has 6.07 million shares and Flynn James E has 3.93 million shares. Over the past six months, insider transactions show net selling. They sold 223.21 thousand shares across 5 transactions.